HDAC6 and plasma cell myeloma: Using a MS-based immunopeptidomics approach, we characterized the effect of HDAC6 inhibitors on the antigenic landscape of multiple myeloma cells and identified canonical antigens and neoantigens upregulated by proteasome activation.